Epigenetic biomarkers in colorectal cancer diagnostics

Expert Review of Molecular Diagnostics

Volumn 12, Issue 5, 2012, Pages 499-509

  Rawson, James B ^a,b   Bapat, Bharati ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

biomarkers; colorectal cancer; diagnosis; DNA methylation; epigenetic; miRNA; plasma; prediction; prognostication; stool

Indexed keywords

APC PROTEIN; BETA CATENIN; BIOLOGICAL MARKER; DEXI PROTEIN; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; HISTONE DEACETYLASE 2; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; OXALIPLATIN; PPARG PROTEIN; PROTEIN MLH1; PROTEIN MSH2; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 4; SECRETED FRIZZLED RELATED PROTEIN 5; SEPT9 PROTEIN; TRANSCRIPTION FACTOR TFAP2E; UNCLASSIFIED DRUG; VIMENTIN; WNT PROTEIN;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SCREENING; CANCER SURVIVAL; COLONOSCOPY; COLORECTAL CANCER; CPG ISLAND; DIAGNOSTIC ACCURACY; EPIGENETICS; FECES ANALYSIS; GENE DELETION; GENE EXPRESSION; GENE SILENCING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTONE MODIFICATION; HUMAN; LONG INTERSPERSED REPEAT; MALIGNANT TRANSFORMATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NUCLEOTIDE REPEAT; OCCULT BLOOD TEST; PREDICTION; PROTEIN EXPRESSION; PROTEIN METHYLATION; RADIOSENSITIVITY; REVIEW; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; TREATMENT RESPONSE; WNT SIGNALING PATHWAY;

COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; GENOMIC INSTABILITY; HISTONES; HUMANS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862520692     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.39     Document Type: Review

References (89)

1. Pawa N, Arulampalam T, Norton JD. Screening for colorectal cancer: established and emerging modalities. Nat. Rev. Gastroenterol. Hepatol. 8(12), 711-722 (2011)
2. Crea F, Nobili S, Paolicchi E et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist. Updat. 14(6), 280-296 (2011)
3. van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol. 29(10), 1382-1391 (2011)
4. Kanai Y, Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 28(12), 2434-2442 (2007) (Pubitemid 350238944)
5. Nagasaka T, Goel A, Notohara K et al. Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int. J. Cancer 122(11), 2429-2436 (2008) (Pubitemid 351590474)
6. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 8(12), 686-700 (2011)
7. Lynch HT, Lynch JF, Shaw TG. Hereditary gastrointestinal cancer syndromes. Gastrointest. Cancer Res. 4(4 SUPPL. 1), S9-S17 (2011)
8. Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis. 14(9), 3-17 (2012)
9. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 36(5), 497-501 (2004) (Pubitemid 38620035)
10. Chan TL, Yuen ST, Kong CK et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet. 38(10), 1178-1183 (2006) (Pubitemid 44470364)
11. Niessen RC, Hofstra RM, Westers H et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 48(8), 737-744 (2009)
12. Ligtenberg MJ, Kuiper RP, Chan TL et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat. Genet. 41(1), 112-117 (2009)
13. Balaguer F, Moreira L, Lozano JJ et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin. Cancer Res. 17(19), 6239-6249 (2011)
14. Lanza G, Ferracin M, Gafa R et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer 6, 54 (2007)
15. Carmona FJ, Esteller M. Moving closer to a prognostic DNA methylation signature in colon cancer. Clin. Cancer Res. 17(6), 1215-1217 (2011)
16. Lind GE, Danielsen SA, Ahlquist T et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol. Cancer 10, 85.
17. Chen WD, Han ZJ, Skoletsky J et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl Cancer Inst. 97(15), 1124-1132 (2005) (Pubitemid 41511211)
18. Zou H, Harrington JJ, Shire AM et al. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol. Biomarkers Prev. 16(12), 2686-2696 (2007) (Pubitemid 351196325)
19. Itzkowitz S, Brand R, Jandorf L et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol. 103(11), 2862-2870 (2008)
20. Song BP, Jain S, Lin SY et al. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J. Mol. Diagn. 14(2), 112-119 (2012)
21. Shirahata A, Sakuraba K, Goto T et al. Detection of vimentin (VIM) methylation in the serum of colorectal cancer patients. Anticancer Res. 30(12), 5015-5018 (2010)
22. Luo YX, Chen DK, Song SX, Wang L, Wang JP. Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-analysis. Int. J. Clin. Pract. 65(12), 1313-1320 (2011)
23. Connolly D, Yang Z, Castaldi M et al. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res. 13(4), R76 (2011)
24. Grutzmann R, Molnar B, Pilarsky C et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 3(11), e3759 (2008)
25. de Vos T, Tetzner R, Model F et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 55(7), 1337-1346 (2009)
26. Warren JD, Xiong W, Bunker AM et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9, 133 (2011)
27. Ahlquist DA, Taylor WR, Mahoney DW et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol. 10(3), 272-277 (2012)
28. He Q, Chen HY, Bai EQ et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet. Cytogenet. 202(1), 1-10 (2010)
29. Syed Sameer A, Shah ZA, Abdullah S, Chowdri NA, Siddiqi MA. Analysis of molecular aberrations of Wnt pathway gladiators in colorectal cancer in the Kashmiri population. Hum. Genomics 5(5), 441-452 (2011)
30. Yu J, Tao Q, Cheng YY et al. Promoter methylation of the Wnt/?-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 115(1), 49-60 (2009)
31. Rawson JB, Manno M, Mrkonjic M et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis 32(5), 741-747 (2011)
32. Qi J, Zhu YQ, Luo J, Tao WH. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J. Gastroenterol. 12(44), 7113-7117 (2006) (Pubitemid 44890639)
33. Suzuki H, Watkins DN, Jair KW et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36(4), 417-422 (2004) (Pubitemid 38437267)
34. Muller HM, Oberwalder M, Fiegl H et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363(9417) 1283-1285 (2004) (Pubitemid 38496491)
35. Huang ZH, Li LH, Yang F, Wang JF. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J. Gastroenterol. 13(6), 950-954 (2007) (Pubitemid 46470311)
36. Oberwalder M, Zitt M, Wontner C et al. SFRP2 methylation in fecal DNA - a marker for colorectal polyps. Int. J. Colorectal Dis. 23(1), 15-19 (2008) (Pubitemid 350142355)
37. Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J. Gastroenterol. 14(4), 524-531 (2008) (Pubitemid 351320817)
38. Zhang W, Bauer M, Croner RS et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis. Colon Rectum 50(10), 1618-1626; discussion 1626-1627 (2007) (Pubitemid 47583343)
39. Lee BB, Lee EJ, Jung EH et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin. Cancer Res. 15(19), 6185-6191 (2009)
40. Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol. Biomarkers Prev. 20(7), 1272-1286 (2011)
41. Link A, Balaguer F, Shen Y et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev. 19(7), 1766-1774 (2010)
42. Koga Y, Yasunaga M, Takahashi A et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev. Res. (Phila.) 3(11), 1435-1442 (2010)
43. Ng EK, Chong WW, Jin H et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58(10), 1375-1381 (2009)
44. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 127(1), 118-126 (2010)
45. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008)
46. Vogt M, Munding J, Gruner M et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 458(3), 313-322 (2011)
47. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 57(7), 941-950 (2008) (Pubitemid 351919529)
48. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J. Clin. Oncol. 28(20), 3380-3387 (2010)
49. Shima K, Morikawa T, Baba Y et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control 22(2), 301-309 (2011)
50. Murakami J, Lee YJ, Kokeguchi S et al. Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol. Rep. 17(6), 1461-1467 (2007)
51. Nagasaka T, Sharp GB, Notohara K et al. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin. Cancer Res. 9(14), 5306-5312 (2003) (Pubitemid 37413584)
52. Nakajima TE, Yamada Y, Shimoda T et al. Combination of O6-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy. Eur. J. Cancer 44(3), 400-407 (2008)
53. Shulman K, Cohen I, Barnett-Griness O et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 117(14), 3156-3162 (2011)
54. Glimelius B, Garmo H, Berglund A et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 11(1), 61-71 (2011)
55. Belanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol. Biol. 11, 9 (2010)
56. Miyaki Y, Suzuki K, Koizumi K et al. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer. Int. J. Oncol. 40(1), 217-226 (2012)
57. Pancione M, Sabatino L, Fucci A et al. Epigenetic silencing of peroxisome proliferator-activated receptor ? is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One 5(12), e14229 (2010)
58. Ebert MP, Tanzer M, Balluff B et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N. Engl. J. Med. 366(1), 44-53 (2012)
59. Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 115(6), 1492-1502 (2005) (Pubitemid 40814658)
60. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, Kim H. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int. J. Cancer 121(3), 567-575 (2007) (Pubitemid 46986490)
61. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D, Tai IT. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br. J. Cancer 98(11), 1810-1819 (2008) (Pubitemid 351748842)
62. Plummer R, Vidal L, Griffin M et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin. Cancer Res. 15(9), 3177-3183 (2009)
63. Shen L, Catalano PJ, Benson AB 3rd, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res. 13(20), 6093-6098 (2007) (Pubitemid 350075067)
64. Ogino S, Meyerhardt JA, Kawasaki T et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 450(5), 529-537 (2007) (Pubitemid 46676250)
65. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 9(8), 2898-2903 (2003) (Pubitemid 36993247)
66. Ahn JB, Chung WB, Maeda O et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117(9), 1847-1854 (2011)
67. Ogino S, Nosho K, Kirkner GJ et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl Cancer Inst. 100(23), 1734-1738 (2008)
68. Min BH, Bae JM, Lee EJ et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 11, 344 (2011)
69. Baba Y, Huttenhower C, Nosho K et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol. Cancer 9, 125 (2010)
70. Kawakami K, Matsunoki A, Kaneko M, Saito K, Watanabe G, Minamoto T. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci. 102(1), 166-174 (2011)
71. Sunami E, de Maat M, Vu A, Turner RR, Hoon DS. LINE-1 hypomethylation during primary colon cancer progression. PLoS One 6(4), e18884 (2011)
72. Schepeler T, Holm A, Halvey P et al. Attenuation of the ?-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene doi:10.1038/onc.2011.453 (2011) (Epub ahead of print)
73. Chang KH, Miller N, Kheirelseid EA et al. MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur. J. Surg. Oncol. 37(7), 597-603 (2011)
74. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 79(3-4), 313-320 (2010)
75. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299(4), 425-436 (2008) (Pubitemid 351185951)
76. Valeri N, Gasparini P, Braconi C et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl Acad. Sci. USA 107(49), 21098-21103 (2010)
77. Schepeler T, Reinert JT, Ostenfeld MS et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 68(15), 6416-6424 (2008)
78. Lujambio A, Calin GA, Villanueva A et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. Sci. USA 105(36), 13556-13561 (2008)
79. Kamimae S, Yamamoto E, Yamano HO et al. Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors. Cancer Prev. Res. (Phila.) 4(5), 674-683 (2011)
80. Weichert W, Roske A, Niesporek S et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 14(6), 1669-1677 (2008) (Pubitemid 351469450)
81. Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J. Gastroenterol. 16(19), 2421-2427 (2010)
82. Fluge O, Gravdal K, Carlsen E et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br. J. Cancer 101(8), 1282-1289 (2009)
83. Takawa M, Masuda K, Kunizaki M et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102(7), 1298-1305 (2011)
84. Lee CC, Chen WS, Chen CC et al. TCF12 protein functions as transcriptional repressor of E-cadherin, and its overexpression is correlated with metastasis of colorectal cancer. J. Biol. Chem. 287(4), 2798-2809 (2012)
85. Crea F, Fornaro L, Paolicchi E et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann. Oncol. 23(5), 1207-1213 (2012)
86. Arai E, Kanai Y. DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status. Epigenomics 2(3), 467-481 (2010)
87. Kudo Y, Tateishi K, Yamamoto K et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 103(4), 670-676 (2012)
88. Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH, Park DI. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis. Colon Rectum 52(8), 1452-1459; discussion 1459-1463 (2009)
89. Jover R, Nguyen TP, Perez-Carbonell L et al. 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer Gastroenterology 140(4)1174-1181 (2011)